---
schema_version: "secwatch.filing_event.v1"
accession: "0001055726-25-000056"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:13:24.471893+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inovio Q2 net loss narrows to $23.5M; BLA for INO-3107 on track for 2H25 submission

## Summary
- Net loss $23.5M ($0.61/share) vs $32.2M ($1.19/share) YoY; total operating expenses $23.1M down from $33.3M.
- Completed CELLECTRA 5PSP device DV testing; requested rolling BLA submission for INO-3107 by year end.
- Cash, cash equivalents, and short-term investments $47.5M at June 30; plus $22.5M from July offering, supporting ops into Q2 2026.
- Long-term INO-3107 data published: 86% of patients had 50-100% reduction in surgeries by Year 2; mean surgeries reduced from 4.1 to 0.9.
- R&D expenses fell to $14.5M from $23.1M, reflecting lower drug manufacturing and clinical costs.

## SEC filing metadata
- accession: 0001055726-25-000056
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/0001055726-25-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/ino-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001055726-25-000056
- JSON: https://secwatch.observer/filing/0001055726-25-000056.json
- Plain text: https://secwatch.observer/filing/0001055726-25-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.